Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Eleni P. Kotanidou, Christos P. Kotanidis, Styliani Giza, Anastasios Serbis, Vasiliki-Regina Tsinopoulou, Paraskevi Karalazou, Georgios Tzimagiorgis & Assimina Galli-Tsinopoulou. (2019) Osteoprotegerin increases parallel to insulin resistance in obese adolescents. Endocrine Research 44:1-2, pages 9-15.
Read now
Read now
Martina Montagnana, Giuseppe Lippi, Elisa Danese & Gian Cesare Guidi. (2013) The role of osteoprotegerin in cardiovascular disease. Annals of Medicine 45:3, pages 254-264.
Read now
Read now
Articles from other publishers (16)
Ilias D. Vachliotis & Stergios A. Polyzos. (2023) Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease. Current Obesity Reports 12:2, pages 147-162.
Crossref
Crossref
Tae Ryom Oh, Chana Myeong, Su Hyun Song, Hong Sang Choi, Sang Heon Suh, Chang Seong Kim, Eun Hui Bae, Wookyung Chung, Kyu Hun Choi, Kook Hwan Oh, Seong Kwon Ma & Soo Wan Kim. (2022) Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study). Kidney Research and Clinical Practice 41:2, pages 200-208.
Crossref
Crossref
Angela Mei Chung Moh, Sharon Li Ting Pek, Jianjun Liu, Jiexun Wang, Tavintharan Subramaniam, Keven Ang, Chee Fang Sum, Pek Yee Kwan, Simon Biing Ming Lee, Wern Ee Tang & Su Chi Lim. (2020) Plasma osteoprotegerin as a biomarker of poor glycaemic control that predicts progression of albuminuria in type 2 diabetes mellitus: A 3-year longitudinal cohort study. Diabetes Research and Clinical Practice 161, pages 107992.
Crossref
Crossref
Rolf Jorde, Astrid Kamilla Stunes, Julia Kubiak, Guri Grimnes, Per Medbøe Thorsby & Unni Syversen. (2019) Smoking and other determinants of bone turnover. PLOS ONE 14:11, pages e0225539.
Crossref
Crossref
Kyriaki Karavanaki, Emmanouil Tsouvalas, Marina Vakaki, Alexandra Soldatou, Charalambos Tsentidis, George Kaparos, Areti Augoulea, Andreas Alexandrou & Ιrene Lambrinoudaki. (2018) Carotid intima media thickness and associations with serum osteoprotegerin and s-RANKL in children and adolescents with type 1 diabetes mellitus with increased risk for endothelial dysfunction. Journal of Pediatric Endocrinology and Metabolism 0:0.
Crossref
Crossref
Lena Tschiderer, Gerhard Klingenschmid, Rajini Nagrani, Johann Willeit, Jari A. Laukkanen, Georg Schett, Stefan Kiechl & Peter Willeit. (2018) Osteoprotegerin and Cardiovascular Events in High‐Risk Populations: Meta‐Analysis of 19 Prospective Studies Involving 27 450 Participants. Journal of the American Heart Association 7:16.
Crossref
Crossref
Peng Duan, Min Yang, Meilin Wei, Jia Liu & Ping Tu. (2017) Serum Osteoprotegerin Is a Potential Biomarker of Insulin Resistance in Chinese Postmenopausal Women with Prediabetes and Type 2 Diabetes. International Journal of Endocrinology 2017, pages 1-8.
Crossref
Crossref
Yixin Niu, Weiwei Zhang, Zhen Yang, Xiaoyong Li, Wenjun Fang, Hongmei Zhang, Suijun Wang, Houguang Zhou, Jiangao Fan, Li Qin & Qing Su. (2016) Plasma osteoprotegerin levels are inversely associated with nonalcoholic fatty liver disease in patients with type 2 diabetes: A case–control study in China. Metabolism 65:4, pages 475-481.
Crossref
Crossref
Yixin Niu, Zhen Yang, Xiaoyong Li, Weiwei Zhang, Shuai Lu, Hongmei Zhang, Xueru Chen, Lingfei Zhu, Yin Xing, Guang Ning, Li Qin & Qing Su. (2015) Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION study. BMC Endocrine Disorders 15:1.
Crossref
Crossref
Raelene E. Maser, M. James Lenhard, Michael B. Sneider & Ryan T. Pohlig. (2015) Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes. Endocrine Practice 21:1, pages 14-22.
Crossref
Crossref
C. Pérez de Ciriza, A. Lawrie & N. Varo. (2015) Osteoprotegerin in Cardiometabolic Disorders. International Journal of Endocrinology 2015, pages 1-15.
Crossref
Crossref
Ezgi Kalaycıoğlu, Tayyar Gökdeniz, Ahmet Çağrı Aykan, Engin Hatem, Mustafa Ozan Gürsoy, Asım Ören, Hüseyin Yaman, Ayşe Gül Karadeniz & Şükrü Çelik. (2014) Osteoprotegerin Is Associated With Subclinical Left Ventricular Systolic Dysfunction in Diabetic Hypertensive Patients: A Speckle Tracking Study. Canadian Journal of Cardiology 30:12, pages 1529-1534.
Crossref
Crossref
Joshua R. Lewis, Wai H. Lim, Kun Zhu, Germaine Wong, Satvinder S. Dhaliwal, Ee M. Lim, Thor Ueland, Jens Bollerslev & Richard L. Prince. (2014) Elevated Osteoprotegerin Predicts Declining Renal Function in Elderly Women: A 10-Year Prospective Cohort Study. American Journal of Nephrology 39:1, pages 66-74.
Crossref
Crossref
Hanis H. Harith, Margaret J. Morris & Mary M. Kavurma. (2013) On the TRAIL of obesity and diabetes. Trends in Endocrinology & Metabolism 24:11, pages 578-587.
Crossref
Crossref
Areti Augoulea, Nikolaos Vrachnis, Irene Lambrinoudaki, Konstantinos Dafopoulos, Zoe Iliodromiti, Angelos Daniilidis, Michail Varras, Andreas Alexandrou, Efthymios Deligeoroglou & George Creatsas. (2013) Osteoprotegerin as a Marker of Atherosclerosis in Diabetic Patients. International Journal of Endocrinology 2013, pages 1-6.
Crossref
Crossref
Woori NaCheongmin Sohn. (2011) Association of Plasma Osteoprotegerin with Adiponectin and Difference according to Obesity in Men with Metabolic Syndrome. Korean Journal of Community Nutrition 16:6, pages 762.
Crossref
Crossref